|
Chloroquine
|
2.17–2.27
|
Diagnosis and Treatment Protocol of COVID-19 (Trial Version 6)
|
2.19
|
Notice on Adjusting the Usage and Dosage of Chloroquine Phosphate in Treating COVID-19 on a Trial Basis
|
2.28
|
|
Mask
|
2.17–3.18
|
Notice on Issuing the Technical Guidelines on the Selection and Use of Masks Used for Prevention and Control of COVID-19 in Different Populations
|
2.05
|
Notice on Issuing the Guidelines on the Scientific Wearing of Masks
|
3.18
|
|
Infectious disease transmission, patient-to-professional
|
3.18–4.17
|
Notice on Further Strengthening Protection of Medical Staff during COVID-19 Prevention and Control
|
2.19
|
Notice on Further Strengthening Infection Prevention and Control at Medical Institutions during COVID-19
|
3.13
|
|
Telemedicine
|
2.17–2.27
|
Notice on Effectively Conducting Internet-Based Diagnosis, Treatment, and Consultation Service Work during COVID-19 Prevention and Control
|
2.07
|
Notice on Conducting Online Services to Further Strengthen COVID-19 Prevention and Control Work in Hubei Province
|
2.26
|
|
Patient discharge
|
2.27–3.08
|
Diagnosis and Treatment Protocol of COVID-19 (Trial Version 6)
|
2.19
|
Diagnosis and Treatment Protocol of COVID-19 (Trial Version 7)
|
3.04
|
